Unknown PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT05602792

A Study of T3011 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumors

A Phase I/IIa Study to Assess the Safety, Tolerability, Biodistribution and Pharmacodynamic of T3011 Herpes Virus Administered Via Intratumoral Injection in Patients With Advanced Solid Tumors.

Sponsor: ImmVira Pharma Co. Ltd

Conditions Advanced Solid Tumor Breast Cancer Esophagus Cancer HNSCC NSCLC Non-melanoma Skin Cancer Sarcoma

Interventions T3011

Updated 4 times since 2022 Last updated: Oct 30, 2022 Started: Apr 21, 2020 Primary completion: Jul 31, 2023 Completion: Jan 31, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Advanced Solid Tumor and Breast Cancer, this trial is ongoing. The trial is conducted by ImmVira Pharma Co. Ltd and has accumulated 4 data snapshots since 2020. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

4 versions recorded

Nov 2024 — Present [monthly]

Unknown PHASE1/PHASE2

Status: Recruiting → Unknown
Sep 2024 — Nov 2024 [monthly]

Recruiting PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Dec 2022 — Jul 2024 [monthly]

Recruiting PHASE1_PHASE2

First recorded

Apr 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

ImmVira Pharma Co. Ltd

Data source: ImmVira Pharma Co. Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Beijing, China , Changsha, China , Chengdu, China , Guanzhou, China , Hanzhou, China , Hefei, China , Nanchang, China , Shanghai, China , Shenyang, China , Shenzhen, China and 2 more locations